<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365248">
  <stage>Registered</stage>
  <submitdate>4/11/2013</submitdate>
  <approvaldate>4/11/2013</approvaldate>
  <actrnumber>ACTRN12613001208796</actrnumber>
  <trial_identification>
    <studytitle>Ticagrelor and platelet reactivity in acute coronary syndromes</studytitle>
    <scientifictitle>Acute Coronary Syndrome patients and the effects of ticagrelor loading dose on level of platelet inhibition</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acute Coronary Syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Randomised, double-blind clinical trial comparing the effects of a single 180mg Ticagrelor loading dose given orally (control) with a single 360mg Ticagrelor loading dose given orally (intervention) on platelet inhibition in patients with acute coronary syndromes. This is the initial treatment, following which patients will undergo angiography. Depending on the findings at angiography patients may be prescribed dual anti platelet therapy (ticagrelor and aspirin) daily for up to 1 year, but this is beyond the scope of this study, which is only investigating the effects of the initial loading dose. </interventions>
    <comparator>180mg Ticagrelor compared to 360mg Ticagrelor loading dose.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Level of platelet inhibition measured using platelet impedance aggregometry at 2 hours (using Multiplate system).</outcome>
      <timepoint>2 hours after loading dose</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Level of platelet inhibition measured using platelet impedance aggregometry at 1, 4 and 8 hours (using Multiplate system).</outcome>
      <timepoint>at 1 hour, 4 hours and 8 hours after loading dose</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Acute coronary syndrome</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Known platelet function disorder
Platelet count less than 100
Prior administration of a P2Y12 receptor antagonist within 2 weeks</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients with acute coronary syndrome requiring dual antiplatelet therapy will be enrolled in the study.

Random numbers contained in sealed envelopes will be used for study enrolment and treatment allocation</concealment>
    <sequence>Random number allocation using custom written computer software</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>Comparison of level of platelet inhibition at 2 hours using non-parametric statistic (Mann Whitney U test). Based upon the RAPID study ( J Am Coll Cardiol. 2013 Apr 16;61(15):16016) data and the assumption that a difference of more than 20% would be required to be statistically significant, a sample size of 25 per group is required to give 80% probability of detecting this difference at p=0.05.</statisticalmethods>
    <masking1>True</masking1>
    <masking2>False</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>9/12/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>9/06/2014</anticipatedenddate>
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Peter Larsen</primarysponsorname>
    <primarysponsoraddress>University of Otago, Wellington
PO Box 7343
Wellington
6242</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Cardiology Department
Wellington Hospital
</othercollaboratorname>
      <othercollaboratoraddress>Wellington Hospital
Riddiford St
Newton
Wellington 6021</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Following a heart attack we give all patients drugs that act on platelets that circulate in the blood. These drugs, aspirin and ticagrelor, act on the platelets to limit the amount of blood clotting that occurs following the heart attack. The standard amount of ticagrelor we give people initially is 180mg. A study has shown that with this amount of the drug it can take 8 to 12 hours until the full effect of the drug is observed. We want to know if by doubling the initial dose to 360mg we can reduce the time it takes to see the full effects.   </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Heath and Disability Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health
No 1 The Terrace
PO Box 5013
Wellington 6001</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>8/11/2013</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Peter Larsen</name>
      <address>University of Otago, Wellington
PO Box 7343
Wellington 6242</address>
      <phone>+6449185103</phone>
      <fax />
      <email>peter.larsen@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Peter Larsen</name>
      <address>University of Otago, Wellington 
PO Box 7343
Wellington 6242</address>
      <phone>+6449185103</phone>
      <fax />
      <email>peter.larsen@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Peter Larsen</name>
      <address>University of Otago, Wellington 
PO Box 7343
Wellington 6242</address>
      <phone>+6449185103</phone>
      <fax />
      <email>peter.larsen@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Peter Larsen</name>
      <address>University of Otago, Wellington 
PO Box 7343
Wellington 6242</address>
      <phone>+6449185103</phone>
      <fax />
      <email>peter.larsen@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>